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Abstract: Age-related macular degeneration (AMD) is the leading cause of irreversible central 
vision loss in developed countries. With the aging of population, AMD will become globally 
an increasingly important and prevalent disease worldwide. It is a complex disease whose 
etiology is associated with both genetic and environmental risk factors. An extensive decline 
in the quality of life and progressive need of daily living assistance resulting from AMD among 
those most severely affected highlights the essential role of preventive strategies, particularly 
advising patients to quit smoking. In addition, maintaining a healthy diet, controlling other 
risk factors (such as hypertension, obesity, and atherosclerosis), and the use of nutritional 
supplements (antioxidants) are recommendable. Genetic testing may be especially important in 
patients with a family history of AMD. Recently, unifying criteria for the clinical classification 
of AMD, defining no apparent aging changes; normal aging changes; and early, intermediate, 
and late AMD stages, are of value in predicting AMD risk of progression and in establishing 
recommendations for the diagnosis, therapeutic approach, and follow-up of patients. The present 
review is focused on early and intermediate AMD and presents a description of the clinical 
characteristics and ophthalmological findings for these stages, together with algorithms for the 
diagnosis and management of patients, which are easily applicable in daily clinical practice.
Keywords: age-related macular degeneration, early AMD, intermediate AMD, risk factors, 
classification, prevention, nutritional supplementation
Background
Age-related macular degeneration (AMD) is the main cause of blindness in the 
developed world in subjects aged $55 years, mainly with risk factors and genetic 
predisposition, with the number of patients affected being counted in millions and 
likely to increase with the population longevity.1 Irreversible central vision loss is 
highly incapacitating in multiple physical, social, and emotional areas of patients as 
well as is leading to increased health resource utilization and high societal cost burden.2 
A systematic review of 39 population-based studies of AMD published before 2013 
showed a pooled prevalence for an age range of 45–85 years of 8.7%.3 Early detection 
and treatment are critical in increasing the likelihood of retaining good and functional 
vision. However, despite the growth in treatment options for this disease, there is no 
current curative therapy. Of critical importance is attention to modifiable risk factors 
and routine ophthalmic monitoring for opportunities to provide timely interventions 
in the individual patients.4,5
The mechanisms of AMD pathogenesis are still poorly defined. In fact, the 
multifactorial nature of the disease, the complexity of the visual system, and the 
enigma of aging processes make AMD a complex pathology, in which a correct and 
prompt diagnosis is a key point. Two types of AMD, the “dry” (or atrophic) and “wet” 
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(or neovascular) forms of the disease, have been extensively 
described.6,7 However, the current clinical classification 
of AMD defines three stages according to the severity of 
fundus lesions (drusen size and pigmentary abnormalities) 
assessed within 2 disc diameters of the fovea in persons 
aged .55 years.8 This basic clinical classification scale defin-
ing early, intermediate, and late AMD, including geographic 
atrophy and neovascularization, also is of value in predicting 
risk estimates of progressing to advanced AMD stages.8
There is a paucity of updated and comprehensive infor-
mation focused exclusively on early stages of AMD, which 
can be of the interest of clinicians involved in the care of 
elderly people. Therefore, the objective of the present review 
was to present a description of the clinical characteristics 
and ophthalmological findings of early and intermediate 
stages of AMD, together with algorithms for the diagnosis 
and management of patients with direct applicability in 
daily practice. Unlike neovascular (wet) AMD, early stages 
(early and intermediate) of AMD are not usually the focus 
of an in-depth review.
Risk factors
The initial cause of AMD is unknown, although age, genetic 
factors, and active smoking have been clearly identified as 
risk factors for AMD. One of the most significant factors 
associated with age is focal deposition of acellular detritus 
between the retinal pigment epithelium (RPE) and the 
Bruch’s membrane. These deposits known as drusen appear 
as small yellow points in the macula and peripheral retina. 
Phagocytosis of shed photoreceptor rod outer segments by the 
RPE is essential for retinal function. With age, RPE becomes 
less efficient with the accumulation of residual bodies that 
may cause loss of RPE cells. Changes in the thickness or 
composition of the Bruch’s membrane associated with 
age determine an important reduction of fluid and nutrient 
transport, which are vital for the function of photoreceptors. 
Age also causes a 50% reduction in the thickness of choroidal 
vessels and an alteration of the sinusoid structure, which 
together with thickness of the Bruch’s membrane cause 
hypoxia, responsible for secretion of vascular endothelial 
growth factors, which contribute to the development of 
neovessels. On the other hand, an increase in the rigidity of 
the scleral due to age, dyslipidemia, and particularly athero-
sclerosis may affect clearance of lipoproteins, which accumu-
late in the form of drusen in the subretinal space contributing 
to atrophy of photoreceptors. These changes are reflected by 
the increasing prevalence of AMD as subjects are getting 
older. Disease prevalence for late AMD can peak near 10% 
in persons aged .80 years. The prevalence of late AMD is 
1.4% at the age of 70 years, raising to 5.6% at age of 80 and 
to 20% at age of 90.9
In addition to age-related changes, it has been shown that 
genetic factors significantly contribute to risk for advanced 
AMD.10,11 About 20 genes involved in the pathogenesis 
of AMD have been identified, the most important being 
CFH, C3, C2, ARMS2, FB, CFHR4, CFHR5, and F13B. 
The CFH Y402H polymorphism is strongly associated with 
AMD, playing a role in almost 60% of AMD at the popula-
tion level.12 Prevalence rates of this polymorphism vary 
by race, with higher percentages in Caucasians (39%) and 
black people (30%) than in Asian populations (7%).12 The 
importance of this factor has propitiated the development of 
commercially available genetic testing kits, which in addition 
to phenotype data are of value to assess the risk of progres-
sion of the disease.13,14
Epidemiological studies have shown that cigarette 
smoking increases the risk of AMD 2- to 4-fold compared to 
patients who never smoked.15,16 It is postulated that smoking 
affects the pathogenesis of AMD by a variety of mechanisms 
promoting oxidative damage, inducing angiogenesis, impair-
ing the choroidal circulation, and by activating the immune 
system including the complement pathway.17–19 Stopping 
smoking reduces the risk of AMD, and after 20 years of 
cessation, the risk of developing AMD is the same as for 
nonsmokers. Moreover, for people who are homozygous for 
the Y402H allele in CFH, smoking has a multiplicative effect 
on the risk of AMD.20 In this respect, it has been shown that 
genetic risk information for AMD can influence motivation 
to stop smoking.21
Other risk factors for AMD include hypertension, ath-
erosclerosis, family history of AMD, high body mass index, 
high-fat diet, low intake of antioxidants and zinc, previous 
cataract surgery, history of cardiovascular disease, higher 
plasma fibrinogen, and diabetes.22–24
Clinical classification
The development of a novel clinical classification of AMD 
based on an evidence-based investigation using a Delphi 
process has been shown to be a very valuable tool in the 
therapeutic approach of patients with AMD.8 This classifi-
cation system focuses on the clinical phenotype associated 
with the development of large drusen and pigmentary abnor-
malities, leading to neovascular AMD, geographic atrophy, 
or both. The unified classification scheme is easy to use in 
daily practice because it is based on fundus lesions assessed 
within 2 disc diameters of the fovea in people aged .55. 
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As the first step, phenotype characteristics are limited to 
those that can be identified by common ophthalmological 
office equipment (ophthalmoscope and slit lamp with acces-
sory lenses), although other imaging technologies and visual 
function evaluation may be necessary to refine the phenotypes 
of early, intermediate, and late stages of AMD.
The first proposal has been to use the single term “age-
related macular degeneration” for the disease. In addition, 
there is a clear differentiation between the stages of “no 
apparent aging changes” or “normal aging changes” 
characterized by the presence of drupelets only (small 
drusen #63 µm) and “early,” “intermediate,” and “late” 
AMD stages. As shown in Table 1, the severity stages (ie, 
early, intermediate, and late AMD) are established according 
to drusen size and AMD pigmentary abnormalities.8 AMD 
pigmentary abnormalities are defined as hyperpigmentation 
or hypopigmentation present within 2 disc diameters of the 
center of the macula in eyes with drusen $63 µm in diameter 
and without known retinal disease entities or other reasons 
for such abnormalities. Figures 1–11 show the illustrative 
cases of early, intermediate, and late AMD.
Interestingly, a 5-year risk scale using data of the Age-
Related Eye Disease Study (AREDS)25 and based on a 
combination of one or more large drusen ($125 µm) and 
AMD pigmentary abnormalities in the right and left eyes was 
also developed.25 According to ophthalmological findings, 
a maximum score of 2 per eye with a maximum score of 
4 per patient can be established (Table 2). The 5-year risk 
for developing AMD increases by a factor of 100 between 
a score of 0 and a score of 4. The risk of 5-year progression 
to late AMD is 0.5% for score 0 (normal aging changes), 
3% for score 1, 12% for score 2, 25% for score 3, and 50% 
for score 4. The risk estimate can be further modified up or 
Table 1 Clinical classification of AMD based on phenotype 
characteristics
Classification Characteristics
No abnormal 
findings
No aging changes:
•	 Absence of drusen
•	 No pigmentary abnormalities
Normal aging changes:
•	 Drupelets only (small drusen #63 µm)
•	 No pigmentary abnormalities
early AMD •	 Medium-sized drusen .63 µm and #125 µm
•	 No pigmentary abnormalities
Intermediate AMD •	 Large drusen .125 µm and/or pigmentary 
abnormalities
Late AMD •	 Neovascular AMD and/or any 
geographic atrophy
Abbreviation: AMD, age-related macular degeneration.
Figure 1 Normal aging changes, with drupelets only (small drusen #63 µm) and no 
pigmentary abnormalities.
Figure 2 early AMD with medium-sized drusen .63 µm and #125 µm and no 
pigmentary abnormalities.
Abbreviation: AMD, age-related macular degeneration.
down according to the presence or absence of other known 
risk factors (eg, smoking and genetic risk).
Diagnosis
It is important to recognize symptoms suspicious of AMD 
that should alert clinicians to refer the patient to the specialist 
for a complete assessment and to determine the urgency of 
treatment. In a person aged .55 years with good visual acuity 
(VA), alarming signs include the following: 1) progressive or 
sudden decreased vision not improved with optic correction; 
2) central field defect (whether absolute or relative); 3) meta-
morphopsia, micropsias, or macropsias; or 4) difficulties in 
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daily life activities (eg, watching television, going down 
stairs, recognizing people, and going around a corner).
Metamorphopsia is a key symptom in the assessment of 
a patient with AMD. Metamorphopsias is a hallmark sign in 
patients with macular diseases and can be easily recognized 
using the Amsler grid or M-charts.26,27 In the preferential 
hyperacuity perimeter (PHP) test, a single straight dotted line 
with a few dots out of alignment is flashed across different 
macular loci over a macular field of 14°×14°, and the patient 
uses a stylus to touch the screen where he had experienced a 
distortion in the line. Any distortion perceived by the patient 
is automatically recorded and analyzed, and a macular map 
showing the area of distortion and the intensity of metamor-
phopsia is displayed. Although the superiority of this test over 
the Amsler grid in patients with AMD has been reported,28 
similar test performance characteristics for both the Amsler 
grid and PHP to rule out wet AMD in the screening setting 
have been found.29 However, the disadvantage of the PHP 
is its high cost. On the other hand, the macular mapping test 
(MacuFlow),30 which can be used at home because it is freely 
accessible through Internet, requires the cooperation of some-
one who is trained and with good VA as well as considerable 
intellectual ability, making its universal use as a screening 
instrument difficult. The association of the Amsler grid with 
the near vision and reading optotype has been shown to be 
useful for early self-diagnosis in neovascular AMD.31
A visit to the ophthalmologist is essential for a correct 
diagnosis of AMD, including fundus examination with 
dilated pupils or nonmydriatic chamber and assessment of the 
Figure 3 To define intermediate AMD is enough to have one or more large drusen 
($125 µm in the smallest diameter), a distance approximating the width of a major 
branch retinal vessel crossing the optic disc margin.
Abbreviation: AMD, age-related macular degeneration.
Figure 4 Intermediate AMD with small, intermediate, and large drusen, most of 
them outside the macula center.
Note: The yellow circle represents a size of 2 disc diameters showing that there are 
also drusen inside the macular center.
Abbreviation: AMD, age-related macular degeneration.
Figure 5 Intermediate AMD with small, intermediate, and large drusen, most of 
them in the macula center.
Abbreviation: AMD, age-related macular degeneration.
Figure 6 Intermediate AMD with hyperpigmentary or hypopigmentary abnormalities 
associated with some drusen $63 µm in diameter.
Abbreviation: AMD, age-related macular degeneration.
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VA (Early Treatment Diabetic Retinopathy Study optotype). 
Optical coherence tomography (OCT) is recommendable, 
whereas fluorescein angiography is indicated in patients 
with suspicion of choroidal neovascularization membrane. 
In clinical practice, indispensable work-up studies should 
include dilated fundus examination and VA measurement. 
Evaluation of the optic fundus combined with information 
provided by the new clinical classification of AMD is a basic 
tool for the diagnosis of the disease, identification of AMD 
stage in the individual patient, and planning of therapeutic 
strategies and follow-up.
Commercial genetic testing using a sample of saliva 
and examining a number of main genetic biomarkers for 
AMD are now widely available through physicians’ offices. 
Genetic information has been shown to be of value to predict 
progression to the advanced forms of AMD, choroidal 
neovascularization, and geographic atrophy32–34 as well as 
to improve patient management. However, the routine use 
of genetic testing is not supported by the existing literature 
and is not recommended at this time. Prospectively designed 
clinical trials are still needed to validate the use of genetic 
testing in AMD.35
In the presence of changes in the epiretinal membrane, 
fundus autofluorescence imaging will help to identify better 
the characteristics and details of these findings (Figure 11).
Management and follow-up
Recommendations regarding the therapeutic approach and 
follow-up of patients are based on a definitive diagnosis of the 
Figure 7 Late AMD with large drusen, hyperpigmentary and hypopigmentary 
abnormalities, and geographic atrophy.
Abbreviation: AMD, age-related macular degeneration.
Figure 8 Late neovascular AMD with a choroidal neovascularization surrounding 
by subretinal hemorrhages.
Abbreviation: AMD, age-related macular degeneration.
Figure 9 Late AMD with both neovascular signs (choroidal neovascularization with 
subretinal hemorrhages) and geographic atrophy.
Abbreviation: AMD, age-related macular degeneration.
Figure 10 Late AMD in a disciform stage secondary to neovascular AMD.
Note: Subretinal fibrosis, lipid exudates, hyperpigmentary and hypopigmentary 
abnormalities, and geographic atrophy are present.
Abbreviation: AMD, age-related macular degeneration.
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stage of the disease based on the results of ophthalmological 
examinations and application of the clinical classification 
of AMD.
In patients with early AMD, it is important to identify 
modifiable lifestyle risk factors especially to advise to quit 
smoking36–39 and to improve a balanced and healthy diet 
rich in fruits, vegetables (natural antioxidants), and bluefish 
(the primary source of omega-3 polyunsaturated fatty 
acids [PUFAs], such as docosahexaenoic acid [DHA] and 
eicosapentaenoic acid [EPA]).40–51 Other risk factors (eg, 
hypertension, atherosclerosis, and overweight) present in 
the individual patient should be controlled.52 Genetic testing 
may be recommendable based on a personalized approach, 
with particular indication in patients with a family history of 
AMD.35 The patient should be instructed to use the Amsler 
grid with the lines on a black background to assess the appear-
ance of any distortions or breaks in the lines of the grid. 
In the absence of any manifestation suggestive of progression 
of AMD, patients should be followed at 12-month intervals.
In patients with intermediate AMD, recommendations are 
focused on evaluation and correction of risk factors especially 
on quitting smoking and taking antioxidants as a dietary 
supplementation.35,52 In addition, self-assessment using the 
Amsler grid on a black background together with the reading 
optotype should be recommended, with follow-up controls 
scheduled at 6-month intervals. However, it is important to 
warn the patient that if he/she perceives a sudden change in 
vision before the next visit, an urgent consultation with the 
ophthalmologist is necessary.
Different studies have provided consistent evidence of 
the benefits of treatment with antioxidants (ie, vitamin E, 
vitamin C, lutein and zeaxanthin, zinc, and copper) in the 
intermediate AMD stage. The AREDS53 showed a statisti-
cally significant odds reduction for the development of 
advanced AMD with antioxidants (ie, vitamin C, vitamin E, 
and beta-carotene) plus zinc. In the AREDS2,54 lutein and 
zeaxanthin were used as an appropriate carotenoid substitute. 
The addition of DHA and EPA to the AREDS formulation 
was not associated with a significant improvement in the 
risk reduction of progression to late AMD in this popula-
tion. However, compared to the AREDS, the population 
was older, the patients had a more severe disease, and the 
number of participants in each study group was smaller. 
Antioxidant, vitamin, and mineral supplementation as per the 
original AREDS and AREDS2 trials should be considered 
in patients with intermediate AMD. Numerous studies have 
shown the benefits of higher dietary intake of food rich in 
omega-3 long-chain PUFAs to reduce the risk of AMD and 
the progression of the disease,44–51,55 as well as the risk of late 
AMD in cases of genetic susceptibility.56 Although the role of 
omega-3 fatty acids on the pathogenic mechanisms of AMD 
is currently unresolved, wide circumstantial evidences from 
epidemiological studies and preclinical in vivo and in vitro 
research are strongly supportive.57,58
???????????????????°??????????
??????
Figure 11 Fundus autofluorescence picture of the left eye of a patient with advanced 
geographic atrophy AMD.
Abbreviation: AMD, age-related macular degeneration.
Table 2 Ophthalmological findings determined by clinical 
examination or evaluation of fundus photographs to assess risk 
categories for late AMD
Eyes Findings Score Risk 
score
Right 1) One or more large drusen ($125 µm 
in the smallest diameter), a distance 
approximating the width of a major branch 
retinal vessel crossing the optic disc margin
No =0
Yes =1 1
2) Any definitive hyperpigmentary or 
hypopigmentary abnormalities associated 
with at least some drusen $63 µm in 
diameter, but not associated with known 
retinal disease entities or other reasons for 
such abnormalities
No =0
Yes =1 1
Left 1) One or more large drusen ($125 µm 
in the smallest diameter), a distance 
approximating the width of a major branch 
retinal vessel crossing the optic disc margin
No =0
Yes =1 1
2) Any definitive hyperpigmentary or 
hypopigmentary abnormalities associated 
with at least some drusen $63 µm in 
diameter, but not associated with known 
retinal disease entities or other reasons for 
such abnormalities
No =0
Yes =1 1
Abbreviation: AMD, age-related macular degeneration.
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Experimental studies have shown that lead and cadmium 
accumulate in human ocular tissues, particularly in the RPE 
and choroid.59 An in vitro study on a human RPE cell line 
showed a reduction in intracellular cadmium (Cd[2+]) levels 
by coexposure with manganese.60 In humans, cadmium 
content in retinal tissue seems to increase as a function of 
age and tobacco smoking. In addition, higher cadmium 
levels have been found in neural retina and RPE for AMD 
eyes compared with controls.61,62 In this respect, whether 
heavy metal adsorbents (eg, natural zeolites) might have 
an application for removing metal ions in eye tissues is 
still speculative.
Melatonin has been shown to scavenge hydroxyl radi-
cals and to protect RPE from oxidative damage. It has been 
postulated that the physiological decrease of melatonin in 
aged people may be an important factor in RPE dysfunc-
tion. Clinical studies have shown that the daily use of 3 mg 
melatonin seems to protect the retina and to delay macular 
degeneration.63–65 Integrin peptide therapy is also an emerging 
new class of treatment for wet AMD.66 The understanding 
of AMD pathogenesis could provide innovative therapeutic 
approaches to AMD. Therefore, more research into the early 
phases of AMD is warranted.
Finally, Tables 3 and 4 show the algorithms for the diag-
nosis, management, and follow-up of patients with early and 
intermediate AMD. These proposed algorithms are simple 
and easy to be implemented in clinical practice.
Concluding remarks
The recent clinical classification of AMD is a remarkable 
advance in unifying criteria for correct diagnosis of the differ-
ent stages of the disease, which is essential to determine the 
risk of progression and the therapeutic approach of patients. 
Smoking is a crucial modifiable risk factor for AMD, and 
all efforts should be made to advise and help patients to 
quit. Minimum examinations required in clinical practice 
for screening of AMD are measurement of VA and dilated 
fundus examination. OCT and fundus autofluorescence are 
rapid, easy, and reliable studies recommendable in the assess-
ment of patients with AMD. Metamorphopsia is a hallmark 
sign that can be detected and quantified using simple methods, 
such as the Amsler grid on a black background. A correct and 
healthy diet is recommendable in early AMD, whereas the 
use of nutritional supplements (antioxidants) is particularly 
indicated in the intermediate stage of the disease. In the pres-
ence of any change of vision, an urgent consultation with the 
Table 3 Recommendations for the diagnosis and management of early AMD
Diagnosis Recommendations Follow-up
Identification of risk factors
Basic indispensable ophthalmological examinations:
•	 visual acuity
•	 Dilated fundoscopy
Recommendable complementary studies:
•	 Spectral domain OCT or swept-source OCT
•	 Color fundus Photography
Genetic test (pending for validation in prospective clinical trials)
Self-assessment with the Amsler grid 
on a black background
Controls scheduled every 12 months 
in the absence of clinical manifestations 
suggestive of the progression of diseaseCorrection of modifiable risk factors:
•	 Smoking cessation
•	 Healthy diet
•	 Other factors (eg, hypertension, 
obesity, and atherosclerosis)
Abbreviations: AMD, age-related macular degeneration; OCT, optical coherence tomography.
Table 4 Recommendations for the diagnosis and management of intermediate AMD
Diagnosis Recommendations Follow-up
Identification of risk factors Self-assessment with the Amsler grid 
on a black background
Controls scheduled every 6 months. 
If progression to advanced AMD 
is made, the patient should be 
referred to a retina specialist
Basic indispensable ophthalmological 
examinations:
•	 visual acuity
•	 Dilated fundoscopy
Correction of modifiable risk factors:
•	 Smoking cessation
•	 Healthy diet
•	 Other factors (eg, hypertension, 
obesity, and atherosclerosis)
Recommendable complementary studies:
•	 Spectral domain OCT or swept-source OCT
•	 Color fundus Photography
•	 Fundus autofluorescence
Antioxidants (nutritional supplements)
Genetic test (pending for validation in prospective 
clinical trials). It is especially recommendable in 
patients with a family history of AMD
Urgent consultation with the 
ophthalmologist in the presence of 
sudden vision changes
Abbreviations: AMD, age-related macular degeneration; OCT, optical coherence tomography.
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ophthalmologist is mandatory. In patients with intermediate 
AMD, follow-ups should be scheduled every 6 months with 
prompt referral to a retinal specialist when the progression 
of the disease is detected.
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